Instituto Medico Quirurgico San Rafael S.A.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Instituto Medico Quirurgico San Rafael S.A., research in cardiovascular diseases focuses on lowering risk and slowing disease progression in people with atherosclerotic cardiovascular disease, elevated lipoprotein(a), non-obstructive coronary artery disease, and hypercholesterolemia. These studies are mainly designed to test new therapies and evaluate how well they reduce plaque buildup, improve lipid levels, and prevent major heart and stroke events.
- Testing treatments aimed at reducing coronary plaque progression and total atheroma burden
- Evaluating approaches to prevent major cardiovascular events such as heart attack and stroke
- Studying therapies for elevated Lp(a) and difficult-to-control cholesterol
The site’s cardiovascular program brings together prevention-focused studies for people with established vascular disease and lipid disorders, reflecting a strong interest in improving long-term heart health.
Nutritional and Metabolic Diseases
Clinical trials in nutritional and metabolic diseases at this hospital are centered on obesity, overweight, chronic weight management, and related conditions such as hypertension and metabolic risk. The main goal is to assess new treatments that can support weight loss, improve body composition, and help reduce the health burden linked to excess weight.
- Studying therapies for obesity and overweight in adults
- Assessing weight-loss treatments that may also support muscle preservation
- Exploring metabolic benefits in people with obesity-related cardiovascular risk
Several trials also look at how weight-focused treatments may improve blood pressure and other cardiometabolic outcomes, making this a major area of research at the site.
Musculoskeletal Diseases
Research in musculoskeletal diseases is mainly aimed at osteoarthritis, especially knee osteoarthritis in people who also live with overweight or obesity. These studies are designed to see whether new therapies can ease joint pain while also supporting weight reduction, which may help improve mobility and daily function.
- Evaluating treatments for knee osteoarthritis and related pain
- Studying whether weight-loss therapies can also improve joint symptoms
- Assessing quality-of-life benefits for people with obesity-related joint disease
This area reflects a practical focus on treatments that address both the mechanical strain of excess weight and the discomfort of chronic joint disease.
Respiratory Tract Diseases
The site also participates in studies of respiratory tract diseases, with a focus on moderate to severe obstructive sleep apnea in adults living with overweight or obesity. The purpose of this research is to test new options that may improve breathing-related sleep disruption and support better overall health in people affected by this common condition.
- Testing therapies for obstructive sleep apnea in adults with excess body weight
- Evaluating improvement in sleep-disordered breathing and symptom control
- Exploring links between sleep apnea treatment and metabolic health
These trials add a respiratory dimension to the site’s broader cardiometabolic research portfolio.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Novo Nordisk A/S3active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG5trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 567 other sites in Spain
Therapeutic Area Benchmark — Spain
Select a therapeutic area to compare against other sites in Spain.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Spain
Market Share
Country: Spain
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Instituto Medico Quirurgico San Rafael S.A.
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization | Novo Nordisk A/S | Phase III | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 12 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 5 | Unknown | 2021-11-26 | 2026-02-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.